Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms

Author:

Pongkunakorn Tanyaporn1ORCID,Manosan Thamonwan1,Surawit Apinya1ORCID,Ophakas Suphawan1,Mongkolsucharitkul Pichanun1ORCID,Pumeiam Sureeporn1,Suta Sophida1,Pinsawas Bonggochpass1,Sookrung Nitat2,Saelim Nawannaporn2,Mahasongkram Kodchakorn2,Prangtaworn Pannathee2,Tungtrongchitr Anchalee2,Tangjittipokin Watip3ORCID,Mangmee Suthee3ORCID,Boonnak Kobporn3ORCID,Narkdontri Tassanee4,Teerawattanapong Nipaporn4,Wanitphadeedecha Rungsima5,Mayurasakorn Korapat1ORCID

Affiliation:

1. Siriraj Population Health and Nutrition Research Group, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

2. Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

3. Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

4. Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

5. Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Abstract

Many patients develop post-acute COVID syndrome (long COVID (LC)). We compared the immune response of LC and individuals with post-COVID full recovery (HC) during the Omicron pandemic. Two hundred ninety-two patients with confirmed COVID infections from January to May 2022 were enrolled. We observed anti-SARS-CoV-2 receptor-binding domain immunoglobulin G, surrogate virus neutralization test, T cell subsets, and neutralizing antibodies against Wuhan, BA.1, and BA.5 viruses (NeuT). NeuT was markedly reduced against BA.1 and BA.5 in HC and LC groups, while antibodies were more sustained with three doses and an updated booster shot than ≤2-dose vaccinations. The viral neutralization ability declined at >84-days after COVID-19 onset (PC) in both groups. PD1-expressed central and effector memory CD4+ T cells, and central memory CD8+ T cells were reduced in the first months PC in LC. Therefore, booster vaccines may be required sooner after the most recent infection to rescue T cell function for people with symptomatic LC.

Funder

Faculty of Medicine Siriraj Hospital, Mahidol University

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference52 articles.

1. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum;Tuekprakhon;Cell,2022

2. Protection against Reinfection with the Omicron BA.2.75 Subvariant;Chemaitelly;N. Engl. J. Med.,2023

3. Scarpa, F., Sanna, D., Benvenuto, D., Borsetti, A., Azzena, I., Casu, M., Fiori, P.L., Giovanetti, M., Maruotti, A., and Ceccarelli, G. (2022). Genetic and structural data on the SARS-CoV-2 omicron BQ.1 variant reveal its low potential for epidemiological expansion. Int. J. Mol. Sci., 23.

4. World Health Organization Thailand (2023, April 30). COVID-19—WHO Thailand Situation Reports. Available online: https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports.

5. UK Health Security Agency (2023). SARS-CoV-2 Variants of Concern and Variants under Investigation in England: Technical Briefing 49.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3